A Phase 3, 182-week, Open-Label, Safety and Tolerability Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension (snOH) in Subjects with Primary Autonomic Failure

  • Iansek, Robert (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusRelinquished
Effective start/end date25/05/219/06/22

Keywords

  • phase 3 study
  • treatment safety
  • treatment efficacy
  • neurodegenerative disorders